Apolipoprotein E (APOE) promoter polymorphism rs405509 (APOE rs405509)

The Apolipoprotein E (APOE) promoter polymorphism rs405509 is a functional DNA sequence variant located in the regulatory region of the APOE gene. This specific polymorphism involves a thymine to guanine (T/G) substitution at position -219 relative to the transcription start site, which creates a consensus binding motif for the transcription factor Nuclear Respiratory Factor 1 (NRF1) [1]. The presence of the G allele enhances the recruitment of NRF1, leading to increased transcriptional activity and higher expression levels of the APOE gene in the brain [2]. As APOE is the primary genetic risk factor for late-onset Alzheimer's disease, this variant significantly influences disease susceptibility, age of onset, and the rate of cognitive decline [3]. While the variant itself is a genomic feature rather than a traditional protein target, it represents a critical regulatory node for potential therapeutic intervention aimed at modulating APOE expression [4]. Currently, there are no approved drugs that directly target this specific DNA motif, although research into antisense oligonucleotides and small molecules that could interfere with this transcription factor-DNA interaction is ongoing [5].

Other names

rs405509APOE -219T/GTh1/E47csAPOE promoter variant

None currently established for direct pharmacological targeting of this DNA motif.